Yoram Palti Sells 30,000 Shares of NovoCure Limited (NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) CTO Yoram Palti sold 30,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $18.25, for a total transaction of $547,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Yoram Palti also recently made the following trade(s):

  • On Monday, November 13th, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $17.13, for a total transaction of $513,900.00.
  • On Tuesday, November 7th, Yoram Palti sold 60,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.06, for a total transaction of $1,263,600.00.
  • On Thursday, November 2nd, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.78, for a total transaction of $653,400.00.

NovoCure Limited (NASDAQ:NVCR) opened at $17.60 on Wednesday. The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83. NovoCure Limited has a twelve month low of $6.00 and a twelve month high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.07. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. The firm had revenue of $50.10 million for the quarter, compared to analysts’ expectations of $43.45 million. During the same quarter last year, the company posted ($0.39) earnings per share. NovoCure Limited’s revenue was up 130.9% on a year-over-year basis. equities research analysts forecast that NovoCure Limited will post -0.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/15/yoram-palti-sells-30000-shares-of-novocure-limited-nvcr-stock.html.

Several large investors have recently made changes to their positions in the business. Legal & General Group Plc increased its stake in shares of NovoCure Limited by 8.5% in the second quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 1,092 shares during the period. American International Group Inc. increased its stake in shares of NovoCure Limited by 7.1% in the first quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock valued at $253,000 after purchasing an additional 2,065 shares during the period. Bank of New York Mellon Corp increased its stake in shares of NovoCure Limited by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock valued at $1,406,000 after purchasing an additional 2,480 shares during the period. California State Teachers Retirement System increased its stake in shares of NovoCure Limited by 2.6% in the second quarter. California State Teachers Retirement System now owns 102,309 shares of the medical equipment provider’s stock valued at $1,770,000 after purchasing an additional 2,600 shares during the period. Finally, Teachers Advisors LLC increased its stake in shares of NovoCure Limited by 3.3% in the first quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock valued at $800,000 after purchasing an additional 3,125 shares during the period. Institutional investors own 36.21% of the company’s stock.

NVCR has been the topic of a number of recent research reports. BidaskClub cut shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research cut shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Mizuho initiated coverage on shares of NovoCure Limited in a report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $25.00 target price (down previously from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $21.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply